A patient-derived xenograft pre-clinical trial reveals treatment responses and a resistance mechanism to karonudib in metastatic melanoma

Karonudib (TH1579) is a novel compound that exerts anti-tumor activities and has recently entered phase I clinical testing. The aim of this study was to conduct a pre-clinical trial in patient-derived xenografts to identify the possible biomarkers of response or resistance that could guide inclusion...

Descripción completa

Detalles Bibliográficos
Autores principales: Einarsdottir, Berglind O., Karlsson, Joakim, Söderberg, Elin M. V., Lindberg, Mattias F., Funck-Brentano, Elisa, Jespersen, Henrik, Brynjolfsson, Siggeir F., Olofsson Bagge, Roger, Carstam, Louise, Scobie, Martin, Koolmeister, Tobias, Wallner, Olof, Stierner, Ulrika, Berglund, Ulrika Warpman, Ny, Lars, Nilsson, Lisa M., Larsson, Erik, Helleday, Thomas, Nilsson, Jonas A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6057880/
https://www.ncbi.nlm.nih.gov/pubmed/30042422
http://dx.doi.org/10.1038/s41419-018-0865-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6057880/
https://www.ncbi.nlm.nih.gov/pubmed/30042422
http://dx.doi.org/10.1038/s41419-018-0865-6

Ejemplares similares